RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT03189914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.
Study identification
- NCT ID
- NCT03189914
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2017
- Primary completion
- Sep 30, 2019
- Completion
- Nov 20, 2019
- Last update posted
- Dec 5, 2023
2017 – 2019
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rexahn Site | Tucson | Arizona | 85724 | — |
| Rexahn Site | Weeki Wachee | Florida | 34607 | — |
| Rexahn Site | Joliet | Illinois | 60435 | — |
| Rexahn Site | Skokie | Illinois | 60077 | — |
| Rexahn Site | Lexington | Kentucky | 40503 | — |
| Rexahn Site | Boston | Massachusetts | 02115 | — |
| Rexahn Site | New York | New York | 10065 | — |
| Rexahn Site | Spartanburg | South Carolina | 29303 | — |
| Rexahn Site | Spokane | Washington | 99202 | — |
| Rexahn Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Metastatic Pancreatic Cancer trials
Other public records listing Metastatic Pancreatic Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07707674: Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer Not yet recruiting
- NCT07409272: A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Recruiting
- NCT01174121: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
- NCT06698458: Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer Recruiting
- NCT04222413: Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Recruiting
- NCT06483555: Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03189914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2023 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03189914 live on ClinicalTrials.gov.